The agreement with the FDA on the data requirements for Cytisinicline's NDA submission is a critical regulatory milestone. It suggests that Achieve Life Sciences is on track with its development plans and is making significant progress towards the potential approval of Cytisinicline. This development is likely to be viewed positively by investors, as it reduces regulatory uncertainty and brings the drug one step closer to market, potentially enhancing the company's value.